DEBIOPHARM AND UBIX THERAPEUTICS LAUNCH RESEARCH TO DEVELOP A NEW ANTI-CANCER MODALITY - ANTIBODY DEGRADUCER® CONJUGATES
Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...
mehr